SynthesisBreast cancer research : BCR2015
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.
Synthesis in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study.Breast cancer research : BCR · 2024Article
- Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database.Biomedicines · 2024Article
- Antidiabetic Drugs in Breast Cancer Patients.Cancers · 2024Review
- Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2022Article
- The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms.Frontiers in endocrinology · 2022Review
- A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer.International journal of environmental research and public health · 2020Article
- Dilemmas about instructions for administering drugs and indications for their use: is there negative effect of pharmaceutical industry?Clinical and translational medicine · 2020Article
- Revealing the Interactions Between Diabetes, Diabetes-Related Diseases, and Cancers Based on the Network Connectivity of Their Related Genes.Frontiers in genetics · 2020Article
- Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Diabetes and differences in detection of incident invasive breast cancer.Cancer causes & control : CCC · 2019Article
- Metformin as an adjuvant in breast cancer treatment.SAGE open medicine · 2019Review
- SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia.Cancer & metabolism · 2019Article
- Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study.Breast cancer research : BCR · 2018Observational
- Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus.Clinical and experimental medicine · 2018Article
- Insulin glargine affects the expression ofIranian journal of basic medical sciences · 2018Article
- The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.BMC cancer · 2018Article
- Article
- Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production.Breast cancer research : BCR · 2017Article
- Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?Nature reviews. Clinical oncology · 2017Review
- Diabetes and Breast Cancer Subtypes.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral studies have suggested that anti-diabetic insulin analogue treatment might increase cancer risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment and breast cancer development, and plausible mechanisms.
methodA systematic literature search was performed on breast cell-line, animal and human studies using the key words 'insulin analogue' and 'breast neoplasia' in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the included in vitro studies.
resultsIn total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10 showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment and an increased breast cancer risk (HR 1.04; 95 % CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies were underpowered and suffered from methodological limitations.
conclusionThere is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.